

10 June 2005

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

Revised Appendix 3B

On 8 June 2005, Resonance Health Limited (**Company**) lodged with ASX an Appendix 3B new issue announcement for the issue of securities to minority shareholders in Inner Vision Biometrics Pty Ltd. The appendix 3B contained errors in relation to the class of securities applied for ASX quotation and herewith submits the attached revised Appendix 3B to correct this information. Of the total 68,140,438 ordinary shares issued, 67,000,000 ordinary shares remain in voluntary escrow with 50% escrowed for 6 months and 50% escrowed for 12 months from date of issue.

For ASX listing purposes, all 68,140,438 new ordinary shares form part of the ASX quoted ordinary share class.

We apologise for this error.

Yours sincerely,



Stuart Usher
Joint Company Secretary

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Resonance Health Limited <REVISED APPENDIX 3B>

ABN

96 006 762 492

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | |
|--|--|
| 1 +Class of +securities issued or to be issued | Fully Paid Ordinary Shares – Quoted Performance Shares Class F |
| 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued | 68,140,438 Ordinary Fully Paid Quoted 5,000,000 Class F Performance Shares |
| 3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | – Class F Performance Shares Each Class F share will be converted into one ordinary share upon achievement of Medicare Services Advisory Committee (MSAC) assessment completed and reimbursement number received for at least one clinical application of the IVB technology & the expiration of 12 months from issue date of class F Performance Shares. |

| <p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | <p>Ordinary – yes</p> <p>Performance Shares – only on conversion</p> | | | | | | | | | |
|--|---|--------|--------|-------------|-----------------|------------|---|------------|---|--|
| <p>5 Issue price or consideration</p> | <p>Ordinary Shares - \$0.14 per share</p> <p>Performance Shares - \$0.0001 per share</p> | | | | | | | | | |
| <p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p> | <p>Issued on acquisition of minority shareholders in Inner Vision Biometrics Pty Ltd as approved by shareholders in General Meeting dated 31 May 2005.</p> | | | | | | | | | |
| <p>7 Dates of entering +securities into uncertificated holdings or despatch of certificates</p> | <p>2 June 2005</p> | | | | | | | | | |
| <p>8 Number and +class of all +securities quoted on ASX (<i>including</i> the securities in clause 2 if applicable)</p> | <table border="1"> <thead> <tr> <th data-bbox="779 1218 1055 1260">Number</th> <th data-bbox="1055 1218 1421 1260">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="779 1260 1055 1344">179,494,023</td> <td data-bbox="1055 1260 1421 1344">Ordinary Shares</td> </tr> <tr> <td data-bbox="779 1344 1055 1428">44,461,309</td> <td data-bbox="1055 1344 1421 1428">Options – 15 cents on or before 15/1/07</td> </tr> <tr> <td data-bbox="779 1428 1055 1516">20,605,194</td> <td data-bbox="1055 1428 1421 1516">Options – 40 cents on or before 15/1/08</td> </tr> </tbody> </table> | Number | +Class | 179,494,023 | Ordinary Shares | 44,461,309 | Options – 15 cents on or before 15/1/07 | 20,605,194 | Options – 40 cents on or before 15/1/08 | |
| Number | +Class | | | | | | | | | |
| 179,494,023 | Ordinary Shares | | | | | | | | | |
| 44,461,309 | Options – 15 cents on or before 15/1/07 | | | | | | | | | |
| 20,605,194 | Options – 40 cents on or before 15/1/08 | | | | | | | | | |

+ See chapter 19 for defined terms.

| | | |
|---|------------|--|
| Number and class of all securities not quoted on ASX (including the securities in clause 2 if applicable) | 800,000 | Options – 40 cents on or before 07/7/09 |
| | 1,600,000 | Options – 30 cents on or before 07/7/09 |
| | 4,000,000 | Options – 20 cents on or before 12/11/07 |
| | 3,333,333 | Options – 20 cents on or before 6/12/2007 |
| | 3,333,333 | Options – 30 cents on or before 6/12/2007 |
| | 3,333,333 | Options – 20 cents on or before 1/2/2008 |
| | 3,333,334 | Options – 30 cents on or before 1/2/2008 |
| | 13,000,000 | IVBH Incentive shares <u>IVBH Incentive options</u> |
| | 3,333,334 | Options – 20 cents, 3 years from date of issue |
| | 3,333,333 | Options – 30 cents, 3 years from date of issue |

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable

Part 2 - Bonus issue or pro rata issue

- | | | |
|----|---|--|
| 11 | Is security holder approval required? | |
| 12 | Is the issue renounceable or non-renounceable? | |
| 13 | Ratio in which the +securities will be offered | |
| 14 | +Class of +securities to which the offer relates | |
| 15 | +Record date to determine entitlements | |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | |
| 17 | Policy for deciding entitlements in relation to fractions | |
| 18 | Names of countries in which the entity has +security holders who will not be sent new issue documents | |
| | <p>Note: Security holders must be told how their entitlements are to be dealt with.</p> <p>Cross reference: rule 7.7.</p> | |
| 19 | Closing date for receipt of acceptances or renunciations | |

+ See chapter 19 for defined terms.

- 20 Names of any underwriters
- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders
- 25 If the issue is contingent on +security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do +security holders sell their entitlements *in full* through a broker?
- 31 How do +security holders sell *part* of their entitlements through a broker and accept for the balance?

+ See chapter 19 for defined terms.

32 How do +security holders dispose of their entitlements (except by sale through a broker)?

33 +Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional +securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

| | | |
|----|--|--|
| 38 | Number of securities for which +quotation is sought | |
| 39 | Class of +securities for which quotation is sought | |
| 40 | Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: <ul data-bbox="347 745 724 1014" style="list-style-type: none">• the date from which they do• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | |
| 41 | Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) | |

+ See chapter 19 for defined terms.

Number and +class of all +securities quoted on ASX (including the securities in clause 38)

| Number | +Class |
|--------|--------|
| | |

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

+ See chapter 19 for defined terms.

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Stuart Usher
Joint Company Secretary

10 June 2005

+ See chapter 19 for defined terms.